UTILIZATION OF ANTIDEPRESSANTS IN EPILEPSY
By Ceren Ozkartal (PhD in Pharmacology)
Why Is Depression in Epilepsy a Critical Concern?
Depression is a significant concern for individuals with epilepsy, affecting about one-third of this population and profoundly impacting their quality of life. This high prevalence of depression may be attributed to the challenges of living with epilepsy, but also potential shared neurobiological factors between the two conditions. While the stresses of epilepsy are understandable, it is critical to emphasize that depression is not simply a reaction to the condition, but a serious comorbidity requiring proper medical attention. Untreated depression in epilepsy patients can lead to a multitude of negative consequences, such as decreased quality of life, increased cognitive deficits, higher healthcare utilization, and even heightened risk of suicide and SUDEP (Sudden Unexpected Death in Epilepsy). Therefore, providing adequate antidepressant medication support to epilepsy patients is not only important, but crucial to their overall well-being and long-term health outcomes.
Are Antidepressants a Blessing or a Risk for Epilepsy?
Antidepressants are frequently prescribed to manage depression, but concerns about potential seizure exacerbation can lead to undertreatment of depression in people with epilepsy. Therefore, the multifaceted view of how antidepressants impact epilepsy, encompasses both potential benefits and risks.
Potential Benefits: Some evidence suggests newer antidepressants might positively affect seizure control. It was found that second-generation antidepressants like SSRIs may decrease seizure frequency. However, the exact mechanisms behind this effect are not fully understood, and research has primarily focused on short-term effects on excitability rather than long-term effects on epileptogenesis. Evidence from Human Studies: Research on human subjects has yielded mixed results. Some studies show no worsening of seizure frequency with long-term SSRI/SNRI treatment. Some patients even experience complete seizure freedom, though others see an increase in seizures. Limitations of these studies include small sample sizes, lack of double-blind randomized controlled trials, and the possibility of confounding factors like fluctuating seizure frequency. Overall, this shift in understanding provides hope for individuals seeking relief from depression without jeopardizing their seizure control.
Evidence from Animal Models: Animal studies present a mixed picture, with results varying depending on the model used. SSRIs and SNRIs often show beneficial effects in models of chronic partial epilepsy, while potentially being detrimental in acute seizure models. This underscores the importance of using models that accurately reflect human epilepsy.
Proconvulsant Effects of Older Antidepressants: First-generation antidepressants, particularly TCAs, have been shown to increase seizure susceptibility in both humans and animal models. This has led to caution among clinicians in prescribing antidepressants to people with epilepsy.
Increased Risk of Epilepsy/Seizures: A large cohort study highlighted a statistically significant increase in the risk of epilepsy/seizures for all antidepressant classes and several individual drugs. This risk appears to increase with dose for SSRIs, while for TCAs and other antidepressants, the middle dose categories showed the highest risk. Notably, it was found that trazodone, lofepramine, and venlafaxine carried the highest risks. However, the absolute risk is stated to remain low, particularly for short-term treatment.
Knowing these, we now have a painted complex picture of antidepressant use in epilepsy patients. While newer antidepressants like SSRIs and SNRIs appear to have minimal negative impact on seizure frequency and might even offer some benefits, there is still evidence pointing towards an increased risk of epilepsy/seizures. The variability in research findings, particularly from animal models, highlights the need for further investigation, especially focusing on long-term effects and epileptogenesis.
Longer-term antidepressant use leading to a moderate, accumulating absolute risk of epilepsy/seizures, varies depending on the specific drug prescribed. This underscores the importance of individual risk-benefit assessments for patients considering antidepressant treatment, especially for those with mild, recurring depression or those with additional risk factors for seizures.
What’s Available Beyond Pills?
Empowering individuals with epilepsy and depression requires open communication with healthcare providers. Patients experiencing mood changes, including depression or anxiety symptoms, should discuss these concerns with their healthcare providers. A consultation with a psychiatrist, particularly a neuropsychiatrist with specialized training in neurological disorders, may be beneficial. Engaging in informed discussions about potential risks and benefits of medication can empower patients to make informed decisions about their treatment.
It is equally important to explore alternative treatment options beyond medication. Talk therapy, support groups, cognitive-behavioral therapy, stress management techniques, and exercise can contribute to improving mood and overall well-being in people with epilepsy and their caregivers.
Conclusion
While antidepressants offer a potential avenue for managing depression in individuals with epilepsy, careful consideration of individual circumstances, including the choice of antidepressant, dose, duration, and potential risks and benefits, is essential. Continued research is needed to further investigate the long-term impact of antidepressant use on epilepsy, taking into account various factors such as seizure type, severity, and individual predispositions. This might be able to provide valuable insights for further empowering lives through comprehensive support for individuals with epilepsy.
Bibliography
Maguire MJ, Marson AG, Nevitt SJ. Antidepressants for people with epilepsy and depression. Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No.: CD010682. DOI: 10.1002/14651858.CD010682.pub3.
Iyengar S. Antidepressants in Epilepsy. Epilepsy Foundation. Reviewed June 20, 2016.
Cardamone L, Salzberg MR, O’Brien TJ, Jones NC. Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol. 2013 Jan;168(2):313-29. doi: 10.1111/bph.12052. Epub 2012 Nov 16. PMID: 23157465; PMCID: PMC3539422.
Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015 Nov 10;15:274. doi: 10.1186/s12888-015-0701-9. PMID: 26556316; PMCID: PMC4640669.
